Logo image of DVAX

DYNAVAX TECHNOLOGIES CORP (DVAX) Stock Fundamental Analysis

USA - NASDAQ:DVAX - US2681582019 - Common Stock

10.1 USD
0 (0%)
Last: 10/3/2025, 8:00:01 PM
10.1 USD
0 (0%)
After Hours: 10/3/2025, 8:00:01 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to DVAX. DVAX was compared to 536 industry peers in the Biotechnology industry. Both the profitability and the financial health of DVAX get a neutral evaluation. Nothing too spectacular is happening here. DVAX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

DVAX had positive earnings in the past year.
DVAX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: DVAX reported negative net income in multiple years.
Of the past 5 years DVAX 4 years had a positive operating cash flow.
DVAX Yearly Net Income VS EBIT VS OCF VS FCFDVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

1.2 Ratios

DVAX has a Return On Assets of -5.74%. This is amongst the best in the industry. DVAX outperforms 87.50% of its industry peers.
DVAX's Return On Equity of -10.67% is amongst the best of the industry. DVAX outperforms 88.25% of its industry peers.
Industry RankSector Rank
ROA -5.74%
ROE -10.67%
ROIC N/A
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
DVAX Yearly ROA, ROE, ROICDVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

DVAX's Profit Margin has declined in the last couple of years.
The Gross Margin of DVAX (82.83%) is better than 86.01% of its industry peers.
DVAX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for DVAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
DVAX Yearly Profit, Operating, Gross MarginsDVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DVAX has been reduced compared to 1 year ago.
DVAX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DVAX has a worse debt to assets ratio.
DVAX Yearly Shares OutstandingDVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DVAX Yearly Total Debt VS Total AssetsDVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.39, we must say that DVAX is in the distress zone and has some risk of bankruptcy.
DVAX has a better Altman-Z score (1.39) than 62.87% of its industry peers.
DVAX has a debt to FCF ratio of 3.95. This is a good value and a sign of high solvency as DVAX would need 3.95 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.95, DVAX belongs to the top of the industry, outperforming 93.28% of the companies in the same industry.
DVAX has a Debt/Equity ratio of 0.53. This is a neutral value indicating DVAX is somewhat dependend on debt financing.
DVAX has a Debt to Equity ratio of 0.53. This is in the lower half of the industry: DVAX underperforms 72.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 3.95
Altman-Z 1.39
ROIC/WACCN/A
WACC9.15%
DVAX Yearly LT Debt VS Equity VS FCFDVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.65 indicates that DVAX has no problem at all paying its short term obligations.
The Current ratio of DVAX (6.65) is better than 66.60% of its industry peers.
DVAX has a Quick Ratio of 6.01. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.01, DVAX is doing good in the industry, outperforming 63.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.65
Quick Ratio 6.01
DVAX Yearly Current Assets VS Current LiabilitesDVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 186.36% over the past year.
Measured over the past years, DVAX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.10% on average per year.
DVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.67%.
The Revenue has been growing by 51.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)26.67%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%

3.2 Future

Based on estimates for the next years, DVAX will show a very strong growth in Earnings Per Share. The EPS will grow by 58.55% on average per year.
DVAX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.25% yearly.
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DVAX Yearly Revenue VS EstimatesDVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
DVAX Yearly EPS VS EstimatesDVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 31.56, DVAX can be considered very expensive at the moment.
92.91% of the companies in the same industry are more expensive than DVAX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.86. DVAX is around the same levels.
A Price/Forward Earnings ratio of 20.42 indicates a rather expensive valuation of DVAX.
Based on the Price/Forward Earnings ratio, DVAX is valued cheaply inside the industry as 92.91% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of DVAX to the average of the S&P500 Index (23.32), we can say DVAX is valued inline with the index average.
Industry RankSector Rank
PE 31.56
Fwd PE 20.42
DVAX Price Earnings VS Forward Price EarningsDVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, DVAX is valued cheaply inside the industry as 91.60% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, DVAX is valued cheaper than 95.52% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.93
EV/EBITDA 37.16
DVAX Per share dataDVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as DVAX's earnings are expected to grow with 58.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.78%
EPS Next 3Y58.55%

More info and screens

0

5. Dividend

5.1 Amount

DVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYNAVAX TECHNOLOGIES CORP

NASDAQ:DVAX (10/3/2025, 8:00:01 PM)

After market: 10.1 0 (0%)

10.1

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners98.07%
Inst Owner Change0%
Ins Owners0.56%
Ins Owner Change-11.93%
Market Cap1.18B
Analysts80
Price Target24.48 (142.38%)
Short Float %11.82%
Short Ratio8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.28%
Min EPS beat(2)-86.66%
Max EPS beat(2)30.1%
EPS beat(4)3
Avg EPS beat(4)-9.07%
Min EPS beat(4)-86.66%
Max EPS beat(4)30.1%
EPS beat(8)6
Avg EPS beat(8)79.21%
EPS beat(12)9
Avg EPS beat(12)63.09%
EPS beat(16)10
Avg EPS beat(16)25.23%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-3.96%
Max Revenue beat(2)7.97%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-6.08%
Max Revenue beat(4)7.97%
Revenue beat(8)3
Avg Revenue beat(8)-0.53%
Revenue beat(12)7
Avg Revenue beat(12)3.41%
Revenue beat(16)9
Avg Revenue beat(16)9.62%
PT rev (1m)0%
PT rev (3m)0.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.09%
EPS NY rev (1m)-4.79%
EPS NY rev (3m)-6.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.69%
Valuation
Industry RankSector Rank
PE 31.56
Fwd PE 20.42
P/S 3.75
P/FCF 17.93
P/OCF 15.53
P/B 2.4
P/tB 2.41
EV/EBITDA 37.16
EPS(TTM)0.32
EY3.17%
EPS(NY)0.49
Fwd EY4.9%
FCF(TTM)0.56
FCFY5.58%
OCF(TTM)0.65
OCFY6.44%
SpS2.7
BVpS4.21
TBVpS4.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.74%
ROE -10.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.83%
FCFM 20.89%
ROA(3y)10.61%
ROA(5y)3.5%
ROE(3y)17.99%
ROE(5y)-8.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-15.64%
PM growth 5YN/A
GM growth 3Y10.73%
GM growth 5Y12.85%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 3.95
Debt/EBITDA 35.01
Cap/Depr 124.44%
Cap/Sales 3.23%
Interest Coverage N/A
Cash Conversion 1023.9%
Profit Quality N/A
Current Ratio 6.65
Quick Ratio 6.01
Altman-Z 1.39
F-Score5
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)107.38%
Cap/Depr(5y)141.26%
Cap/Sales(3y)1.68%
Cap/Sales(5y)6.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)186.36%
EPS 3Y-19.1%
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y-347.92%
EPS Next 2Y65.78%
EPS Next 3Y58.55%
EPS Next 5YN/A
Revenue 1Y (TTM)26.67%
Revenue growth 3Y-14.23%
Revenue growth 5Y51.1%
Sales Q2Q%29.33%
Revenue Next Year20.52%
Revenue Next 2Y18.53%
Revenue Next 3Y17.48%
Revenue Next 5Y15.25%
EBIT growth 1Y94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year185.54%
EBIT Next 3Y81.5%
EBIT Next 5YN/A
FCF growth 1Y-55.18%
FCF growth 3Y-43.07%
FCF growth 5YN/A
OCF growth 1Y-49.89%
OCF growth 3Y-41.69%
OCF growth 5YN/A